12:00 AM
May 07, 2001
 |  BioCentury  |  Strategy

Vertex's 2-front plan for Aurora

Outsourcing is often a cheap way for companies to get work done, particularly for focused uses. But once a company decides that it wants to apply a technology across all of its programs, paying for services may become prohibitively expensive. Thus Vertex Pharmaceuticals Inc. decided it would be more cost-effective to acquire Aurora Biosciences Inc. for its ultra-high throughput cell-based assays.

At the same time, VRTX hopes to make ABSC's service component work inside its integrated drug development business, even if toolkit services have proven tough for most companies to sustain as a robust business model.

VRTX thus plans not only to continue servicing ABSC's existing partners but to seek new partners for the newly acquired cell-based assay systems (see "Aurora's Partners"). ABSC is projecting...

Read the full 609 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >